Search Results
You are looking at 1 - 2 of 2 items for
- Author: T. Yoshimasa x
- Refine by access: All content x
Search for other papers by N Hama in
Google Scholar
PubMed
Search for other papers by H Itoh in
Google Scholar
PubMed
Search for other papers by S Suga in
Google Scholar
PubMed
Search for other papers by Y Komatsu in
Google Scholar
PubMed
Search for other papers by T Yoshimasa in
Google Scholar
PubMed
Search for other papers by K Nakao in
Google Scholar
PubMed
Abstract
C-type natriuretic peptide (CNP), the third member of natriuretic peptides, has recently been discovered from the porcine brain. Using a polyclonal antiserum to CNP, we demonstrated that CNP-like immunoreactivity (CNP-LI) is present mainly in the central nervous system. Recently, however, we have discovered the production and secretion of CNP in vascular endothelial cells. These observations suggested that CNP may act not only as a neuropeptide but also as a local regulator of vascular tone or growth. In order to further clarify the pathophysiological significance of CNP, we aimed at the preparation of a monoclonal antibody to CNP.
A monoclonal antibody to CNP, KY-CNP-I, has been produced. This monoclonal antibody belongs to the immunogloblin G1 subclass and has high affinity for CNP. Using this monoclonal antibody, we established a specific radioimmunoassay (RIA) for CNP. The RIA detected CNP-LI in rat brain extracts and culture media conditioned with bovine endothelial cells. In addition, the pretreatment of cultured aortic smooth muscle cells with KY-CNP-I attenuated cyclic GMP production induced by CNP in vitro. The preadministration of KY-CNP-I to rats also attenuated plasma cyclic GMP increase after intravenous injection of CNP in vivo.
These results indicate that this monoclonal antibody is a useful tool to clarify the pathophysiological role of CNP as a neuropeptide and as a local vascular regulator.
Journal of Endocrinology (1994) 141, 473–479
Search for other papers by H. Imura in
Google Scholar
PubMed
Search for other papers by Y. Kato in
Google Scholar
PubMed
Search for other papers by Y. Nakai in
Google Scholar
PubMed
Search for other papers by K. Nakao in
Google Scholar
PubMed
Search for other papers by I. Tanaka in
Google Scholar
PubMed
Search for other papers by H. Jingami in
Google Scholar
PubMed
Search for other papers by T. Koh in
Google Scholar
PubMed
Search for other papers by T. Yoshimasa in
Google Scholar
PubMed
Search for other papers by T. Tsukada in
Google Scholar
PubMed
Search for other papers by M. Suda in
Google Scholar
PubMed
Search for other papers by M. Sakamoto in
Google Scholar
PubMed
Search for other papers by N. Morii in
Google Scholar
PubMed
Search for other papers by H. Takahashi in
Google Scholar
PubMed
Search for other papers by K. Tojo in
Google Scholar
PubMed
Search for other papers by A. Sugawara in
Google Scholar
PubMed
ABSTRACT
Advances in techniques in molecular biology have facilitated the research into endogenous opioids and related peptides in several ways. The organization and expression of genes and the primary structure of three precursor proteins of opioid peptides have been elucidated. These studies predicted the presence of potentially bioactive peptides, which has been confirmed by later studies. Advances in techniques in protein chemistry have helped to elucidate the distribution and molecular forms of endogenous opioids and related peptides in the body, and the processing of precursor proteins. Studies on the function of these peptides have shown a broad spectrum of actions. Leumorphin, a newly identified peptide, has been shown to exhibit unique biological activities. In spite of extensive studies, the physiological and pathophysiological significance of opioid peptide systems are not yet completely understood. This is mainly due to the paucity of our knowledge about opioid receptors. Further studies on the subtypes of opioid receptors will help to elucidate all aspects of the function of endogenous opioids and related peptides.
J. Endocr. (1985) 107, 147–157
